After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value and an activist investor is agitating for change.

washingtonpost.com

Read full article on: washingtonpost.com

unread news